News | February 26, 2010

Anti-Platelet Therapy Subject of ACC Lunch Session

February 26, 2010 – The field of cardiovascular therapy is being transformed continuously due to the emergence of new anti-platelet agents possessing unique properties. During ACC 2010, the session “Bleeding: Why Does It Matter?” will discuss these therapies from 12:30-1:30 p.m. Saturday, March 13.

Long-term combination anti-platelet therapy after coronary intervention has been recommended as a means to reduce clinical adverse events. Educational courses on this discipline are needed in order to enhance comprehension of clinical risks and benefits of these new agents, particularly in relation to bleeding.

Lunch will be served between noon and 12:30 p.m. The session is being held in room A305 of the Georgia World Congress Center, 285 Andrew Young International Blvd., NW, Atlanta.

The event is sponsored by the Cardiovascular Research Foundation and supported by an independent medical education grant from the Bristol-Myers Squibb/Sanofi Pharmaceuticals partnership. This event is not part of the official ACC Annual Scientific Session and/or the ACC’s Innovation in Intervention: i2.

To register online visit:

Related Content

Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Overlay Init